Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
79.43 USD | -1.68% | -4.05% | +2.82% |
May. 22 | Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target | MT |
May. 16 | Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 72.24 and 57.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.15% | 12.73B | B+ | ||
+58.56% | 63.85B | B- | ||
-1.47% | 41.83B | B | ||
+41.82% | 40.47B | A | ||
-10.02% | 27.17B | C | ||
+12.27% | 26.52B | B- | ||
-21.60% | 18.69B | B | ||
+23.43% | 12.11B | B+ | ||
+28.84% | 12.07B | C+ | ||
-8.01% | 11.19B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TECH Stock
- Ratings Bio-Techne Corporation